Dr. Reddy’s Laboratories’ shares experienced a slight dip following the announcement of their acquisition of Stugeron from Johnson & Johnson for $50.5 million. This strategic move aims to bolster Dr. Reddy’s Central Nervous System portfolio and expand its presence in the anti-vertigo market across 18 markets in APAC and EMEA, with a focus on India and Vietnam.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets